 |
|
|
| |
No changes in the coding sequence for HBV core protein after 6 weeks of
treatment of HBV infected humanized mice with NVR 3-778
|
| |
| |
Reported by Jules Levin
EASL 2017 April 19-23 Amsterdam Netherlands
A Lam1, T. Shimada2, M Dandri3, L Flores1, K Klumpp1
1Novira Therapeutics, part of the Janssen Pharmaceutical Companies (Doylestown, PA, USA)
2PhoenixBio Co., Ltd. (Higashi-Hiroshima, 739-0046 Japan)
3I. Department of Internal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany and German Center for Infection Research, Hamburg-Lübeck-Borstel Partner Site, Germany
NVR 3-778, a First-in-class HBV Core Inhibitor, Alone and in Combination with Pegylated-interferon (peg-IFN alpha-2a), in Treatment-naïve HBeAg-positive Patients: Early Reductions in HBV DNA and HBeAg - (04/27/16)
(NVR 3-778) Potential first-in-class treatment is well-tolerated in patients with chronic hepatitis B - EASL press release - (04/26/16)
Janssen to Unveil New Hepatitis B and C Data at The International Liver Congress™ 2016 of the European Association for the Study of the Liver (EASL) - (04/07/16)
|
| |
|
|
|
|
|
